Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.65 |
| ▸ | CA2 | P00918 | 2/20 | 0.65 |
| ▸ | PKM | P14618 | 2/20 | 0.52 |
| ▸ | FBP1 | P09467 | 1/20 | 0.52 |
| ▸ | HTR6 | P50406 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | PARL | Q9H300 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL28057150 | 0.88 | CA1 (0.53) | CA1CA2PKMFBP1HTR6 | |
| SCHEMBL28910701 | 0.80 | CA1 (0.46) | CA1CA2PKMFBP1ALDH1A1 | |
| SCHEMBL1364805 | 0.79 | CA1 (1.00) | CA1CA2PKMFBP1ALDH1A1 | |
| SCHEMBL16059915 | 0.79 | CA1 (0.59) | CA1CA2PKMFBP1HTR6 | |
| SCHEMBL3018059 | 0.79 | CA2 (0.64) | CA1CA2PKMFBP1KMT2A | |
| Imidazole SCHEMBL21065544 | 0.79 | CA1 (0.45) | CA1CA2PKMFBP1HTR6 | |
| SCHEMBL12419386 | 0.79 | CA2 (0.58) | CA1CA2PKMFBP1TSHR | |
| SCHEMBL20741109 | 0.77 | CA1 (0.50) | CA1CA2PKMFBP1HTR6 | |
| SCHEMBL28053766 | 0.76 | PKM (0.57) | CA1CA2PKMHTR6ALDH1A1 | |
| SCHEMBL22112764 | 0.75 | PARL (0.48) | CA1CA2PKMHTR6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 397 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12046717-B2 | Nonaqueous electrolyte compositions comprising a fluorinated solvent and a 2-furanone | SYENSQO SA (BE) | 2024-07-23 | — | — | US | claimed |
| WO-2024098538-A1 | METHOD FOR MANUFACTURING SOLAR CELL BY DOPING PEROVSKITE BULK WITH SULFONYL MOLECULES | 中国科学院合肥物质科学研究院 | 2024-05-16 | — | — | WO | claimed |
| CN-114854160-B | Conductive hydrogel based on water-soluble polypyrrole and preparation method thereof | 山东大学 | 2023-03-10 | — | — | CN | claimed |
| CN-115633531-A | Method for preparing solar cell by doping sulfonyl molecules in perovskite phase | 中国科学院合肥物质科学研究院 | 2023-01-20 | — | — | CN | claimed |
| CN-114854160-A | Conductive hydrogel based on water-soluble polypyrrole and preparation method thereof | 山东大学 | 2022-08-05 | — | — | CN | claimed |
| CN-109942543-A | A kind of synthetic method of moxifloxacin hydrochloride light degradation impurity | 山东齐都药业有限公司 | 2019-06-28 | — | — | CN | claimed |
| CN-108383828-A | 1 new, 2- as chemokine receptor modulators is bis--sulfamide derivative | 阿勒根公司 | 2018-08-10 | — | — | CN | claimed |
| EP-2955173-B1 | 1,2-BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2017-10-04 | — | — | EP | claimed |
| US-9603834-B2 | 1,2- bis-sulfonamide derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2017-03-28 | — | — | US | claimed |
| US-20160228407-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. | 2016-08-11 | — | — | US | claimed |
| CN-1422270-A | Salts of bicyclic N-acylated imidazol-3-amines and imidazol-5-amines | GRUELENTHAL GMBH (DE) | 2003-06-04 | — | — | CN | claimed |
| JP-2003511456-A | — | — | 2003-03-25 | — | — | JP | claimed |
| EP-1274709-A1 | SALTS OF BICYCLIC, N-ACYLATED IMIDAZO-3-AMINES AND IMIDAZO-5-AMINES | Grünenthal GmbH (DE) | 2003-01-15 | — | — | EP | claimed |
| US-20020183320-A1 | Bicyclic imidazo-5-yl-amine derivatives | GRUENENTHAL GMBH (DE) | 2002-12-05 | — | — | US | claimed |
| EP-1218383-A2 | BICYCLIC IMIDAZO-5-YL-AMINE DERIVATIVES | Grünenthal GmbH (DE) | 2002-07-03 | — | — | EP | claimed |
| US-6336963-B1 | INK COMPOSITION COMPRISING INK VEHICLE COMPRISING FIRST NITRILE COMPOUND HAVING FIRST VISCOSITY AT MELT TEMPERATURE, VISCOSITY MODIFIER COMPRISING SECOND NITRILE COMPOUND HAVING LOWER VISCOSITY AT MELT TEMPERATURE, COLORANT | XEROX CORPORATION | 2002-01-08 | — | — | US | claimed |
| WO-2001081344-A1 | SALTS OF BICYCLIC, N-ACYLATED IMIDAZO-3-AMINES AND IMIDAZO-5-AMINES | Grünenthal GmbH (DE) | 2001-11-01 | — | — | WO | claimed |
| WO-2001027118-A2 | BICYCLIC IMIDAZO-5-YL-AMINE DERIVATIVES | Grünenthal GmbH (DE) | 2001-04-19 | — | — | WO | claimed |
| WO-2001027119-A2 | SUBSTANCE LIBRARY CONTAINING BICYCLIC IMIDAZO-5-YL-AMINES AND/OR BICYCLIC IMIDAZO-3-YL-AMINES | Grünenthal GmbH (DE) | 2001-04-19 | — | — | WO | claimed |
| US-6106599-A | Inks | XEROX CORPORATION (US) | 2000-08-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228407-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CXCR2, CCR2, CX3CR1 | CA1 3491/4885CA2 1696/4885PKM 3507/4885 |
| US-20020183320-A1 | Bicyclic imidazo-5-yl-amine derivatives | ACHE, P2RX5, CNR1 | CA1 1298/4885CA2 901/4885PKM 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.